Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
News about QIAGEN N.V. (QGEN) centers on its role as a Netherlands-based Sample to Insight company serving life sciences and molecular diagnostics customers worldwide. This news feed aggregates corporate announcements, product updates, regulatory milestones and financial communications directly related to QGEN.
Readers can follow updates on QIAGEN’s five growth pillars: Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON latent tuberculosis testing. Company news often highlights launches and enhancements of automation systems such as QIAcube Connect, QIAsymphony Connect, QIAsprint, QIAmini and EZ2 Connect Fx, as well as new kits like the EZ2 DNA Investigator Sep&Prep Kit for forensic applications.
Regulatory and clinical diagnostics news includes items such as CE-IVDR certification for QIAstat-Dx panels in Europe, U.S. FDA clearance for QIAstat-Dx Rise, and expansions of test menus for respiratory, gastrointestinal and central nervous system infections. These announcements show how QIAGEN positions its platforms in infectious disease and syndromic testing.
Investors and analysts can also track financial and capital markets developments, including quarterly earnings releases furnished on Form 6-K, outlook updates, and capital return actions such as synthetic share repurchase plans that combine direct capital repayments with reverse stock splits. Strategic moves, for example the agreement to acquire Parse Biosciences to expand into single-cell analysis, are another recurring theme in QGEN news.
For users interested in precision oncology, bioinformatics and AI-enabled solutions, QIAGEN’s news includes information on partnerships, new software capabilities within QDI, and integrated Sample to Insight workflows. Bookmark this page to access an organized stream of QGEN-related announcements spanning products, diagnostics, automation, bioinformatics and investor communications.
QIAGEN (NYSE: QGEN) reported Q4 2025 net sales of $540 million (+4% actual, +1% CER) and adjusted diluted EPS of $0.62, ahead of outlook. Full-year 2025 net sales were $2.09 billion (+6% actual, +5% CER) and adjusted diluted EPS $2.40 CER.
Growth pillars delivered $1.49 billion CER (+8% CER) and adjusted operating margin rose to 29.5%, up 80 bps. QGEN returned > $1.1 billion to shareholders, completed Parse and Genoox bolt-ons, and guided 2026 net sales growth of at least 5% CER with adjusted diluted EPS of at least $2.50 CER.
QIAGEN (NYSE:QGEN) unveiled QIAsprint Connect, its first high-throughput benchtop automation system, at SLAS 2026. The compact system processes up to 192 samples per run, offers customizable protocols, a touch-based UI, and sustainability-focused consumables that cut plastic use by up to 50% and packaging by 40%.
QIAGEN also highlighted QIAsymphony Connect for clinical DNA/RNA extraction and QIAmini for low-throughput labs. QIAsprint Connect will be shown live on Feb 9, 2026 at 2:30 p.m. EST.
QIAGEN (NYSE: QGEN) appointed Mark Stevenson as an independent member of the Supervisory Board effective January 23, 2026; he will stand for election at the Annual General Meeting in June 2026. On the same date, Prof. Dr. Ross Levine stepped down from the Supervisory Board following his appointment as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center and will continue as Chair of QIAGEN’s Scientific Advisory Board. Mark Stevenson brings more than 30 years of life‑science operational leadership, most recently as EVP & COO at Thermo Fisher Scientific, and previously as President & COO at Life Technologies and Applied Biosystems. He is an Operating Partner at Fivespan Partners and a board member of Ingersoll Rand. The Supervisory Board now comprises eight members, including Stevenson.
QIAGEN (NYSE: QGEN) will release fourth-quarter 2025 results on Wednesday, February 4, 2026 shortly after 22:05 Frankfurt / 21:05 London / 16:05 New York. A conference call to discuss results is scheduled for Thursday, February 5, 2026 at 15:30 Frankfurt / 14:30 London / 09:30 New York. Investors can join via callback registration, dial-in phone numbers (U.S. +1 646 769 9200; UK +44 (0)20 7769 6464; GER +49 (0)69 254 99300) using Conference ID 3382302, or the live audio webcast. The live service opens 15 minutes before the call; a replay will be available at the provided webcast replay link.
QIAGEN (NYSE: QGEN) set 2026 priorities across five growth pillars — Sample technologies, QIAstat-Dx, QIAcuity, QIAGEN Digital Insights (QDI) and QuantiFERON — to support a goal of at least $2.0 billion combined annual pillar sales in 2028.
Key facts: QIAGEN completed the acquisition of Parse Biosciences and expects ~$40 million in Parse sales in 2026; cumulative placements: QIAstat-Dx >5,200, QIAcuity >3,200. 2026 product plans include three sample prep systems (QIAsymphony Connect, QIAsprint Connect, QIAmini), BCID panel submissions for U.S. clearance and CE-IVDR, expanded QIAcuity assays and AI-enabled QDI offerings. QuantiFERON updates aim to increase throughput up to 75% more patients/hour and deliver results 25% faster on partner platforms.
QIAGEN (NYSE: QGEN) will complete a synthetic share repurchase of approximately $500 million combining a direct capital repayment with a reverse stock split, effective with the last pre-consolidation trading day on January 7, 2026.
Every 20 pre-consolidation shares will be consolidated into 19, reducing issued shares by about 10.9 million from 217.7 million, or roughly a 5% reduction. Following consolidation the company will repay $2.29 per pre-consolidation share from existing cash reserves. QIAGEN says this completes deliveries toward its commitment to return at least $1 billion to shareholders by end-2028 and that additional return measures are under consideration for 2026 and beyond.
QIAGEN (NYSE: QGEN) introduced QIAsymphony Connect at AMP 2025 and began an early access program ahead of a planned full commercial release in mid-2026. The platform builds on >3,000 cumulative placements of the prior generation (end-2024) and promises improved extraction, up to 50% higher throughput in specific liquid biopsy protocols, 2D barcode traceability, LIMS and QIAsphere connectivity, and optimization for high-sensitivity oncology workflows like MRD monitoring.
At AMP, QIAGEN highlighted Sample to Insight CGP workflows with Element Biosciences Trinity technology and a partnership with Myriad Genetics on an HRD assay; early-access data and planned commercial launches are targeted for early 2026 (commercial launch excluding Japan).
QIAGEN (NYSE: QGEN) reported Q3 2025 net sales of $533 million (+6% at actual rates) and adjusted diluted EPS of $0.61, above its outlook. The company raised its FY2025 adjusted diluted EPS target to about $2.38 CER (from $2.35) and reaffirmed net sales growth of about 4–5% CER (core sales ~5–6% CER). Q3 adjusted operating income margin remained strong near 29.6% and operating cash flow was $165 million.
QIAGEN announced the acquisition of Parse Biosciences to enter the single-cell market and approved a $500 million synthetic share repurchase to be completed in January 2026. The CEO will transition after a successor is appointed.
QIAGEN (NYSE: QGEN) will acquire Parse Biosciences to expand its Sample technologies into scalable single-cell solutions. QIAGEN will pay an upfront $225 million in cash, with up to $55 million in milestone payments; the deal is expected to close in December 2025. Parse brings Evercode instrument-free chemistry, the Tahoe-100M dataset (>100 million cells), GigaLab capacity of 2.5 billion cells/year, and use in >3,000 labs. Parse is expected to add ~$40 million revenue in 2026 (~2 percentage points growth) and to be dilutive ~$0.04 EPS in 2026, turning accretive in 2028.
QIAGEN (NYSE: QGEN) launched the EZ2 DNA Investigator Sep&Prep Kit for automated sexual assault sample processing, announced ahead of ISHI 2025 (Nov 3–6, 2025).
The kit runs on EZ2 Connect Fx, can process up to 24 samples in parallel, and delivers sperm-derived DNA ready for downstream profiling or NGS in under 2.5 hours. It uses a novel lysis buffer plus proprietary bead technology to improve sperm recovery and reduce victim DNA carryover while cutting hands-on time and variability versus manual differential extraction.
QIAGEN will showcase the kit and its forensics portfolio at ISHI 2025 in Palm Beach, Florida.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
